Canine parvovirus infection (CPV) is one among several hazard diseases that incorporates a dramatic end and remains a common and vital reason of morbidity and mortality in puppies. The aim of this study is to evaluate the efficacy of local and imported CPV vaccines along with PIND-ORF against the experimentally challenged puppies with the newly identified CPV-2a virus. Forty native breed puppies around 45 days old free from internal and external parasites (as examined clinically) and negative for CPV antibodies (as screened by serum neutralization test) were enrolled, and randomized into five groups (8 animals, each). Vaccinated groups were compared to each other, or to paramunity inducer inoculated group and to neither treatment nor vaccinated group. It was found that both local canine parvovirus and Vanguard are safe and potent vaccines inducing no clinical post-vaccination reaction and high levels of specific CPV antibodies (256) by 30 days post-vaccination. Such vaccines provided 80% protection for challenging puppies against the recent virulent strain (CPV-2a), while, unvaccinated puppies did not withstand the challenging virus infection. Besides, it was noticed that PIND-ORF enhanced the puppies immune response through the 1st 2 weeks post-vaccination, however, it was unable to enhance their ability to guard against the new CPV-2a virus infection strain. So it may be concluded that the currently used CPV vaccines; either the local or imported ones can protect puppies towards new CPV-2a  strain along with paramunity inducer PIND-ORF.